Anti-IL-5 antibodies and uses thereof
By developing new anti-IL-5 antibodies, the problem of importing existing IL-5 antibody drugs is solved, and a cost-effective treatment plan is provided with a significant ability to block IL-5 and IL-5Rα binding ability. Suitable for the treatment of IL-5-related respiratory diseases.
Patent Information
- Application Number
- CN202411161925.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-23
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-08-23
AI Technical Summary
The existing commercial antibody drugs for IL-5 are imported and expensive, resulting in low accessibility and ineffective benefiting more patients.
A novel anti-IL-5 antibody, including specific heavy and light chain variable region amino acid sequences, maintains its affinity and proliferation blocking effect through humanization, and provides therapeutic options through injection-administered form.
The novel anti-IL-5 antibody has a significant ability to block the binding of IL-5 to IL-5Rα, with an affinity greater than 10-11M, effectively reducing immune side reactions, and verified its use in the treatment of IL-5-related respiratory diseases through various assays. Validity.
Smart Images

Figure CN118930650A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine, and specifically relates to anti-IL-5 antibodies and applications thereof. Background Art
[0002] Severe eosinophilic asthma (SEA) is a refractory respiratory disease with poor clinical control. Eosinophils are crucial in the pathogenesis of SEA, causing airway epithelial damage and bronchial remodeling. Eosinophils are associated with a higher frequency of exacerbations, which reduces the patient's lung function. The current treatment for asthma is inhaled corticosteroids, and long-term use can lead to osteoporosis and hypertension. Biologics have a good effect in treating severe asthma. Type 2 inflammation occurs in 50% to 70% of asthma patients, and the production of inflammatory factors IL-5, IL-4, and IL-13 mediated by Th2 cells increases EOS, IgE, and exhaled nitric oxide (FeNO). Therefore, reducing the number of eosinophils by inhibiting proinflammatory factors is a very favorable treatment option for SEA.
[0003] IL-5 is a homodimeric cytokine linked by interchain disulfide bonds. It is essential for regulating the proliferation, activation, and maturation of eosinophils and can promote the release of eosinophils from the bone marrow into the blood circulation. Although Th2 lymphocytes are the main source of IL-5 production, mast cells, type II innate lymphocytes (ILC2s), natural killer T cells, and even eosinophils also express and produce IL-5. IL-5Rα is an IL-5 binding receptor expressed on the surface of mature eosinophils and basophils. The intermediate complex formed after IL-5 binds to IL-5Rα recruits the β common (βc) receptor (CD131) to form a ternary complex, which then activates the JAK / STAT signaling cascade, thereby promoting the proliferation of EOS. Currently available antibodies against IL-5 include mepolizumab and reslizumab, which can neutralize IL-5 levels in the body, thereby reducing the level of eosinophils, inhibiting the differentiation and activation of EOS, and thus reducing the rate of asthma exacerbation. In clinical trials, antibodies against the IL-5 / IL-5Rα complex can reduce the rate of severe asthma exacerbations, improve forced expiratory volume in 1 second (FEV1), reduce the use of oral glucocorticoids, and so on. In addition, since EOS is associated with the formation of mucus, reducing the number of airway eosinophils can subsequently reduce the formation of airway obstruction, thereby improving lung function. Anti-IL-5 antibodies have been shown to be useful as a means of emergency treatment of steroid-refractory acute severe eosinophilic asthma. In addition, the approved mepolizmab antibody targeting IL-5 has been approved for the treatment of granulomatosis with polyangiitis, eosinophilic granuloma, chronic sinusitis with nasal polyps, Churg-Strauss syndrome, and so on.
[0004] Currently, all the monoclonal antibody drugs targeting IL-5 on the market are imported from abroad and are expensive and have low accessibility. Therefore, developing a new anti-IL5 monoclonal antibody for injection has good clinical application prospects and is expected to break the foreign monopoly and benefit more patients. Summary of the invention
[0005] The object of the present invention is to overcome at least one deficiency of the prior art and provide an anti-IL-5 antibody and a use thereof.
[0006] The technical solution adopted by the present invention is: The first aspect of the present invention provides: An anti-IL-5 antibody comprises a heavy chain and a light chain, wherein the three complementary determining regions of the heavy chain variable region include H_CDR1, H_CDR2 and H_CDR3, and the three complementary determining regions of the light chain variable region include L_CDR1, L_CDR2 and L_CDR3, and the amino acid sequences of the complementary determining regions are as follows: H_CDR1: SGYWV (SEQ ID NO.: 1), H_CDR2: SISYSGTTYYNPSLKS (SEQ ID NO.: 2) and H_CDR3: GIPMDS (SEQ ID NO.: 3); L_CDR1: RASESVDSYGNSFMH (SEQ ID NO.: 4), L_CDR2: RASNLES (SEQ ID NO.: 5) and L_CDR3: QQSNEDPYT (SEQ ID NO.: 6).
[0007] In some examples of anti-IL-5 antibodies, the framework region of the heavy chain variable region is a humanized framework region.
[0008] In some examples of anti-IL-5 antibodies, the amino acid sequence of the heavy chain variable region is selected from one of the following: MIL-A97-H, the amino acid sequence of which is shown in SEQ ID NO.: 7; VH1, the amino acid sequence of which is shown in SEQ ID NO.: 9; VH2, the amino acid sequence of which is shown in SEQ ID NO.: 10; VH3, the amino acid sequence of which is shown in SEQ ID NO.: 11; VH4, the amino acid sequence of which is shown in SEQ ID NO.: 12; VH5, the amino acid sequence of which is shown in SEQ ID NO.: 13; VH6, the amino acid sequence of which is shown in SEQ ID NO.: 14; The amino acid sequence of the light chain variable region is selected from the following, and its amino acid sequence is shown in SEQ ID NO.: MIL-A97-L, the amino acid sequence of which is shown in SEQ ID NO.: 8; VL1, the amino acid sequence of which is shown in SEQ ID NO.: 15; VL2, the amino acid sequence of which is shown in SEQ ID NO.: 16; VL3, the amino acid sequence of which is shown in SEQ ID NO.: 17; VL4, the amino acid sequence of which is shown in SEQ ID NO.: 18.
[0009] In some examples of anti-IL-5 antibodies, the combinations of amino acid sequences of the heavy chain variable region and light chain variable region are: MIL-A97-H+MIL-A97-L, VH1+VL1, VH1+VL2, VH1+VL3, VH1+VL4, VH2+VL2, VH2+VL3, VH2+VL4, VH3+VL2, VH3+VL3, VH3+VL4, VH4+VL2, VH4+VL3, VH4+VL4, VH5+VL3, VH5+VL4, VH6+VL3, VH6+VL4.
[0010] In some examples of anti-IL-5 antibodies, the antibody is a monoclonal antibody, a Fab antibody, a single domain antibody or a multivalent antibody. Specific antibodies can be designed in combination with existing technologies.
[0011] The second aspect of the present invention provides: The first aspect of the present invention relates to the use of the anti-IL-5 antibody in the preparation of a drug for treating IL-5 related respiratory diseases.
[0012] In some application examples, the drug is an injection or an inhalant.
[0013] In some application examples, the IL-5-related respiratory disease is selected from severe eosinophilic asthma, granulomatosis with polyangiitis, eosinophilic granuloma, chronic sinusitis with nasal polyps, Churg-Strauss syndrome, and pulmonary eosinophilia.
[0014] The third aspect of the present invention provides: The first aspect of the present invention relates to the use of the anti-IL-5 antibody in the preparation of an IL-5 detection kit.
[0015] A fourth aspect of the present invention provides: A gene encoding the anti-IL-5 antibody according to the first aspect of the present invention.
[0016] The specific gene sequence can be designed and synthesized using existing methods.
[0017] The beneficial effects of the present invention are: The IL-5 antibodies of some embodiments of the present invention have been humanized, retaining their affinity and proliferation blocking effect, and have a significant ability to block the binding of IL-5 to IL-5Rα, with an affinity greater than 10 -11 M, and effectively reduced immune side effects. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] Figure 1 It is the result of the antibody recombinant supernatant binding to human IL-5.
[0019] Figure 2 It is the result of recombinant supernatant ELISA blocking test.
[0020] Figure 3 It is the result of monoclonal antibody FACS blocking test.
[0021] Figure 4 This is the result of the monoclonal antibody TF-1 cell proliferation inhibition test.
[0022] Figure 5 These are the results of epitope analysis of hu39D10 (P33964) and MIL-A97 (P41791).
[0023] Figure 6 These are the results of epitope analysis of Mepolizumab (P33965) and MIL-A97 (P41791).
[0024] Figure 7 It is the result of affinity test.
[0025] Figure 8 and Fig. 9 This is the result of FACS blocking test of MIL-A97 humanized antibody.
[0026] Figure 10 to Figure 14 These are the results of TF-1 proliferation inhibition assays of different MIL-A97 humanized antibodies. DETAILED DESCRIPTION
[0027] The technical solution of the present invention is further explained below in conjunction with examples.
[0028] Example 1: Immunization of mice The grouped BalB / C mice were immunized with proteins A (hIL-5-hFc), B (hIL-5-his), C (cyIL-5-His), and D (hIL-5-hFc+cyIL-5-His). After 4 rounds of routine immunization, serum was collected for titer detection. Then, IL-5-hFc, hIL-5-his, and cyIL-5-His were used as antigens to coat ELISA plates and then tested separately, and all mice were boosted with immunization.
[0029] Example 2: Construction of mouse immune library The RNA from the spleen tissue of each mouse in Example 1 was extracted by Trizol method, and RNA reverse transcription was performed according to the method provided by TaKaRa reverse transcription kit, and PCR amplification was performed using heavy chain and light chain primers with cDNA as template. Referring to the existing method, a Fab phage display library was constructed.
[0030] Example 3: Antibody Screening The experiment used the magnetic bead method and the immune tube method to screen the mouse immune library. The mouse immune phage library in Example 2 was inoculated into 2YT (C + -T + ) medium and cultured with shaking until OD 600 ≈0.5, add Helper Phage to infect for 1 h to 1.5 h, then centrifuge and discard the supernatant, pour into 2YT (C + -K + ) Cultured overnight in culture medium. On the second day, centrifuge to obtain supernatant, add PEG6000, mix well, and place on ice for precipitation. Centrifuge 1 hour later, discard supernatant, add pre-cooled PBS, pipette to dissolve, and prepare phage suspension.
[0031] 3.1 Magnetic bead screening Magnetic bead screening is based on biotin labeling of the antigen protein (human IL-5 or monkey IL-5) and then binding it to magnetic beads coupled with streptavidin. The selection process is carried out by incubating, washing and eluting the antigen-bound magnetic beads and the antibody gene phage display library.
[0032] The mouse immune library bacterial suspension was diluted with 2.5% BSA and blocked for negative screening (the positive screening antigen was labeled with Fc, and negative screening protein was added during incubation, and the amount of negative screening protein was 10 times the amount of positive screening protein), and the phages after negative screening incubation were collected. Binding and washing were performed according to the Kingfisher magnetic bead screening system method, and finally the phages were eluted with Trypsin. Subsequently, the eluted phages were used to infect the SS320 bacteria in the logarithmic growth phase, and the phages finally obtained were used for the next round of panning. After 3-4 rounds of panning, the specific phage pool for IL-5 was finally enriched.
[0033] 3.2 Immunotube screening Immunotube screening is a panning process in which the antigen protein (human IL-5 or monkey IL-5) is coated on the surface of an immunotube with high adsorption capacity, and the phage display antibody library is added to the immunotube and the antigen protein adsorbed on the surface of the immunotube is incubated, washed and eluted.
[0034] 3.3 Single clone selection The clone pool with good enrichment effect was selected for monoclonal plating, and the monoclonal supernatant Fab expression was induced. The ELISA method was used to detect the binding signal of monoclonal supernatant and IL-5 with IL-5 as the antigen. A total of 555 positive clones were obtained. The positive clones were selected for sequencing analysis, and a total of 50 positive antibodies with unique sequences were obtained. Through sequence similarity analysis and modification analysis, 46 antibodies were finally selected for recombinant expression.
[0035] Example 4: Recombinant expression of monoclonal antibodies and detection of IL-5 protein binding activity The heavy chains of 46 Fab sequences were constructed on the pcDNA3.4 vector containing the Fc tag to obtain a recombinant plasmid expressing the complete heavy chain; the light chain was constructed on the pcDNA3.4 vector to obtain a recombinant plasmid expressing the complete light chain. The recombinant plasmid was recombinantly expressed in expi CHO-S cells, and the supernatant was taken for ELISA binding detection.
[0036] Human IL-5-His was diluted to 2 μg / mL with PBS and added to the ELISA plate, 30 μL per well; overnight coating, after washing the plate 5 times with PBST, blocked with 5% milk at 37°C for 1 h, added with gradient dilutions of recombinant antibodies, incubated at 37°C for 1 h, washed the plate 5 times with PBST, added with secondary antibody Anti-human-IgG-Fc-HRP (diluted with PBS 1:10000) and incubated at 37°C for 1 h, then washed 5 times with PBST, added 30 μL of TMB colorimetric solution to each well, reacted at room temperature in the dark for 5 min, then added 2 M sulfuric acid to terminate the reaction, and the absorbance was measured at 450nm with an ELISA reader.
[0037] Figure 1 The binding of some antibody supernatants to human IL-5 is shown, with IPI and milk as negative controls.
[0038] Example 5: ELISA blocking activity detection of recombinant supernatant Dilute hIL-5-hFc to 2 μg / mL with PBS, take 30 μL and add it to the ELISA plate, and incubate it overnight at 4 ℃. Wash the plate 3 times with PBST and block it with 5% milk at room temperature for 2 h. Wash the plate 3 times with PBST, dilute the recombinant antibody to be tested with 1% milk, add it to the ELISA plate, 30 μL per well, and incubate it at room temperature for 1 h. Add hIL-5Rα-cHis (4 μg / mL) without washing the plate, and incubate it at room temperature for 1 h. Wash the plate 3 times with PBST, add 6×his-HRP (proteintech; HRP-66005) antibody diluted 1:4000, and incubate it at room temperature for 1 h. After washing the plate, add 30 μL TMB colorimetric solution to each well, react at room temperature in the dark for 5 min, then add 50 μL 2M sulfuric acid to terminate the reaction, and measure the absorbance at 450 nm with an ELISA reader.
[0039] Figure 2 The results show that some antibody supernatants blocked the binding of IL-5 to IL-5R at the ELISA level. The negative controls are IPI and milk. IPI was not successfully fitted and milk is single-point data.
[0040] Example 6: Antibody purification and blocking activity detection The cell supernatant with blocking effect in Example 5 was purified by protein A purification column, and its purity was analyzed by SDS-PAGE. Referring to the method of Example 5, the purified monoclonal antibody was subjected to ELISA blocking retest.
[0041] The CHO-S stable cell line co-expressing IL-5Rα and CD131 proteins was constructed. The CHO-S-IL-5Rα-CD131 cells were collected by centrifugation, washed with FACS staining buffer and resuspended to prepare a cell suspension. The cell density was adjusted to 1×10 6 cells / mL, centrifuge and discard the supernatant. Refer to the patent CN116606375A method for FACS blocking detection. The results are as follows Figure 3 As shown, MIL-A97 antibody can block the binding of IL-5 to cell surface IL-5Rα at the FACS level. Figure 3 The results show that some antibodies block the binding of IL-5 and IL-5R at the FACS level, among which hIL-5-mFc and cell only are single point data.
[0042] Example 7: Proliferation inhibition assay of recombinant antibody TF-1 The recombinant antibody MIL-A97 was used to detect the proliferation inhibition of TF-1. The specific detection method was carried out according to the method disclosed in CN116606375A. The results are shown in Figure 4As shown, MIL-A97 can significantly inhibit the proliferation of TF-1-IL-5Rα-A17 cell line, and the blocking effect of MIL-A97 is equivalent to that of the positive control hu39D10. The amino acid sequences of the heavy chain variable region and light chain variable region of the MIL-A97 antibody are as follows: MIL-A97 heavy chain variable region: QVQLKESGPSLVKPSQTLSLTCSVTGDSVT- SGp -WIRKFPGNKLEYMG- SISYSGTTYYNPSLKS -RISITRDTSMNQYYLQLNSVTTEDTATYYCAG- GIPMDS -WGQGTSVTVSS (SEQ ID NO.: 7) MIL-A97 light chain variable region: DIVLTQSPASLAVSLGQRATISC- RASESVDSYGNSFMH -WYQQKPGQPPKLLIY- RASNLES -GIPARFSGSGSRTDFTLTINPVEADDVATYYC- QQSNEDPYT -FGGGTKLEIK (SEQ ID NO.: 8).
[0043] In the above amino acid sequence, the italicized regions are the CDR regions determined according to the Kabat database.
[0044] Example 8: Antibody epitope analysis 8.1 Epitope competition analysis with hu39D10 hu39D10 is Reslizumab.
[0045] Human IL-5-His was diluted to 1 μg / mL with PBS, added to the ELISA plate, 30 μL per well, and incubated at 4 °C overnight. After washing the plate three times, it was blocked with 5% skim milk powder at room temperature for 2 h. The antibody to be analyzed was diluted with 1% Milk, added to the ELISA plate, and incubated at room temperature for 1 h. 0.5 μg / mL hu39D10-Biotin was added to the ELISA plate, 30 μL per well, and incubated at room temperature for 1 h. The plate was washed three times with PBST, and NeutrAvidin-HRP (Thermo Fisher; 31001) diluted 1:2000 was added and incubated at room temperature for 1 h. After washing the plate, 30 μL TMB colorimetric solution was added to each well, reacted at room temperature in the dark for 5 min, and then 50 μL 2M sulfuric acid was added to terminate the reaction, and the absorbance was measured at 450 nm by a microplate reader.
[0046] The results are as follows Figure 5 As shown, there is an epitope competition relationship between hu39D10 (P33964) and MIL-A97 (P41791).
[0047] 8.2 Epitope competition analysis between candidate antibodies and mepolizumab Human IL-5-His was diluted to 4 μg / mL with PBS and added to the ELISA plate, 30 μL per well, and incubated at 4 °C overnight. After washing the plate three times, it was blocked with 5% skim milk powder at room temperature for 2 h. The antibody to be analyzed was diluted with 1% Milk, added to the ELISA plate, and incubated at room temperature for 1 h. 0.5 μg / mL Mepolizumab-Biotin-Biotin was added to the ELISA plate, 30 μL per well, and incubated at room temperature for 1 h. The plate was washed three times with PBST, and NeutrAvidin-HRP (ThermoFisher; 31001) diluted 1:2000 was added and incubated at room temperature for 1 h. After washing the plate, 30 μL TMB colorimetric solution was added to each well, reacted at room temperature in the dark for 5 min, and then 50 μL 2M sulfuric acid was added to terminate the reaction, and the absorbance was measured at 450 nm by an ELISA reader.
[0048] The results are as follows Figure 6 As shown, MIL-A97 (P41791) and Mepolizumab (P33965) are not the same epitope.
[0049] Example 9: ELISA-based detection of the binding activity of candidate antibodies to monkey IL-5 protein and mouse IL-5 protein Monkey IL-5-His, rat IL-5-His and mouse IL-5-His proteins were coated on ELISA plates respectively, and MIL-A97 (P41791) was added to detect binding activity. The specific method is shown in Example 4. The results are shown in Table 1.
[0050] Table 1: Results of the binding activity test between MIL-A97 and IL-5 from different animals (EC 50 )
[0051] The results showed that MIL-A97 had cross-reactivity among humans, mice and monkeys.
[0052] Example 10: Antibody Affinity Determination Biacore T200 (Cytiva) was used to measure antibody affinity. Protein A chip was used to capture the antibody to be tested. Different concentrations of antigen IL-5-His were added for affinity testing. The results are shown in Figure 2. Figure 7 And as shown in Table 2.
[0053] Table 2: Antibody affinity determination
[0054] The results show that the affinity of MIL-A97 is comparable to that of the positive control hu39D10.
[0055] Example 11: ELISA binding and blocking detection of MIL-A97 humanized antibody Based on the results of affinity blocking activity detection, the MIL-A97 antibody (named A97-mVH-A97-mVL) was selected for humanization, the germline with the highest similarity to MIL-A97 was selected by IgBlast, the CDR region of MIL-A97 was transplanted, different sites were selected for back mutation, the sequence was synthesized and constructed into an expression vector as shown in Table 3, and expressed in expiCHO-S cells and purified using a protein A protein purification column. ELISA binding and ELISA blocking activity detection were performed according to the methods of Example 4-5, and the results are shown in Table 4.
[0056] Table 3: Amino acid sequences of the heavy and light chain variable regions of the humanized MIL-A97 antibody
[0057] Note: In the table, VH refers to heavy chain and VL refers to light chain.
[0058] Table 4: ELISA activity test results of different humanized monoclonal antibodies against different IL-5 / EC 50 (μg / mL)
[0059] Note: In the table, VH1 to VH6 refer to the heavy chains with the same numbers in Table 3, and VL1 to VL4 refer to the light chains with the same numbers in Table 3.
[0060] Example 11: FACS blocking assay of MIL-A97 humanized antibody The FACS blocking test of the humanized antibody was performed according to the method of Example 6. The results are as follows: Figure 8 and Fig. 9 As shown (where hIL-5-mFc is a single point data), A97-huVH1-A97-huVL1, A97-huVH1-A97-huVL2, A97-huVH1-A97-huVL3, A97-huVH2-A97-huVL2, A97-huVH3-A97-huVL2, A97-huVH3-A97-huVL3, huVH4-A97-huVL2, and A97-huVH4-A97-huVL3 have better blocking effects.
[0061] Example 12: Affinity detection of MIL-A97 humanized antibody The humanized antibodies with good ELISA binding ability, blocking ability, and FACS blocking ability were selected for affinity testing. The affinity of the humanized antibodies was tested according to the method of Example 10. The results shown in Table 5 show that the candidate humanized antibodies have a comparable affinity to the parent antibody.
[0062] Table 5 Humanized antibody affinity test
[0063] Example 13: MIL-A97 humanized antibody TF-1 proliferation inhibition assay Humanized antibodies were used to detect TF-1 proliferation inhibition. The specific detection method refers to patent CN116606375A. The results are as follows Figure 10-14 As shown (IgG1 and Cell+IL-5-hFc are single-point data), the candidate humanized antibodies all have the effect of inhibiting TF-1 cell proliferation.
[0064] The above is a further detailed description of the present invention, which should not be regarded as a limitation on the specific implementation of the present invention. For ordinary technicians in the technical field to which the present invention belongs, simple deduction or replacement without departing from the concept of the present invention is within the protection scope of the present invention.
Claims
1. An anti-IL-5 antibody, comprising a heavy chain and a light chain, wherein the three complementary determining regions of the heavy chain variable region include H_CDR1, H_CDR2 and H_CDR3, and the three complementary determining regions of the light chain variable region include L_CDR1, L_CDR2 and L_CDR3, characterized in that: The amino acid sequence of the complementary determining region is as follows: H_CDR1:SGYWV H_CDR2: SISYSGTTYYNPSLKS H_CDR3:GIPMDS L_CDR1:RASESVDSYGNSFMH L_CDR2:RASNLES L_CDR3:QQSNEDPYT.
2. The anti-IL-5 antibody according to claim 1, characterized in that The framework region of the heavy chain variable region is a humanized framework region.
3. The anti-IL-5 antibody according to claim 1, characterized in that The amino acid sequence of the heavy chain variable region is selected from the following: MIL-A97-H: QVQLKESGPSLVKPSQTLSLTCSVTGDSVTSGYWVWIRKFPGNKLEYMGSISYSGTTYYNPSLKSRISITRDTSMNQYYLQLNSVTTEDTATYYCAGGIPMDSWGQGTSVTVSS VH1: QVQLKESGPGLVKPSQTLSLTCSVTGDSVTSGYWVWIRKHPGKGLEYMGSISYSGTTYYNPSLKSRITISRDTSMNQYYLKLSSVTAADTAVYYCAGGIPMDSWGQGTTVTVSS VH2: QVQLQESGPGLVKPSQTLSLTCSVTGDSVTSGYWVWIRQHPGKGLEYMGSISYSGTTYYNPSLKSRITISRDTSMNQYSLKLSSVTAADTAVYYCAGGIPMDSWGQGTTVTVSS VH3: QVQLQESGPGLVKPSQTLSLTCSVTGDSVTSGYWVWIRQHPGKGLEYMGSISYSGTTYYNPSLKSRVTISRDTSKNQYSLKLSSVTAADTAVYYCAGGIPMDSWGQGTTVTVSS VH4: QVQLQESGPGLVKPSQTLSLTCTVSGDSVTSGYWVWIRQHPGKGLEYMGSISYSGTTYYNPSLKSRVTISRDTSKNQYSLKLSSVTAADTAVYYCAGGIPMDSWGQGTTVTVSS VH5: QVQLQESGPGLVKPSQTLSLTCTVSGDSVTSGYWVWIRQHPGKGLEYIGSISYSGTTYYNPSLKSRVTISRDTSKNQFSLKLSSVTAADTAVYYCAGGIPMDSWGQGTTVTVSS VH6: QVQLQESGPGLVKPSQTLSLTCTVSGDSISSGYWVWIRQHPGKGLEYIGSISYSGTTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAGGIPMDSWGQGTTVTVSS; The amino acid sequence of the light chain variable region is selected from the following: MIL-A97-L: DIVLTQSPASLAVSLGQRATISCRASESVDSYGNSFMHWYQQKPGQPPKLLIYRASNLESGIPARFSGSGSRTDFTLTINPVEADDVATYYCQQSNEDPYTFGGGTKLEIK VL1: DIQLTQSPSSLSVSVGDRATISCRASESVDSYGNSFMHWYQQKPGQPPKLLIYRASNLESGIPARFSGSGSRTDFTLTISSVQAEDFATYYCQQSNEDPYTFGGGTKLEIK VL2: DIQLTQSPSSLSVSVGDRATITCRASESVDSYGNSFMHWYQQKPGKAPKLLIYRASNLESGIPARFSGSGSRTDFTLTISSLQPEDFATYYCQQSNEDPYTFGGGTKLEIK VL3: DIQLTQSPSSSLSASVGDRVTITCRASESVDSYGNSFMHWYQQKPGKAPKLLIYRASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPYTFGGGTKLEIK VL4: DIQMTQSPSSSLSASVGDRVTITCRASESVDSYGNSFMHWYQQKPGKAPKLLIYRASNLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPYTFGGGTKLEIK.
4. The anti-IL-5 antibody according to claim 3, characterized in that The amino acid sequence combinations of its heavy chain variable region and light chain variable region are: MIL-A97-H+MIL-A97-L, VH1+VL1, VH1+VL2, VH1+VL3, VH1+VL4, VH2+VL2, VH2+VL3, VH2+VL4, VH3+VL2, VH3+VL3, VH3+VL4, VH4+VL2, VH4+VL3, VH4+VL4, VH5+VL3, VH5+VL4, VH6+VL3, VH6+VL4.
5. The anti-IL-5 antibody according to claim 1, characterized in that The antibody is a monoclonal antibody, a Fab antibody, a single domain antibody or a multivalent antibody.
6. Use of the anti-IL-5 antibody according to any one of claims 1 to 5 in the preparation of a drug for treating IL-5 related respiratory diseases.
7. The use according to claim 6, characterized in that: The medicine is an injection or an inhalation agent.
8. The use according to claim 6, characterized in that: The IL-5-related respiratory disease is selected from severe eosinophilic asthma, granulomatosis with polyangiitis, eosinophilic granuloma, chronic sinusitis with nasal polyps, Churg-Strauss syndrome, and pulmonary eosinophilia.
9. Use of the anti-IL-5 antibody according to any one of claims 1 to 5 in the preparation of an IL-5 detection kit.
10. A gene encoding the anti-IL-5 antibody according to any one of claims 1 to 5.
Citation Information
Patent Citations
Il-5 antibody, antigen binding fragment thereof, and medical application therefor
CN111065651A
Monoclonal antibody binding to human il-5, preparation method therefor and use thereof
CN111615519A
Anti-human interleukin 5(IL-5) monoclonal antibody and use thereof
CN113366016A
Preparation method and application of antibody for resisting human interleukin-5
CN116589577A
